Qiagen (NYSE:QGEN) Updates Q2 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its second quarter 2026 earnings guidance on Monday. The company provided earnings per share guidance of 0.600- for the period, compared to the consensus earnings per share estimate of 0.620. The company issued revenue guidance of $523.3 million-$523.3 million, compared to the consensus revenue estimate of $554.0 million. Qiagen also updated its FY 2026 guidance to 2.430- EPS.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Stifel Nicolaus set a $50.00 target price on Qiagen and gave the stock a “hold” rating in a research report on Friday, February 6th. Deutsche Bank Aktiengesellschaft raised Qiagen from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research report on Friday, March 13th. Barclays set a $44.00 target price on Qiagen and gave the stock an “equal weight” rating in a research report on Tuesday, April 14th. Robert W. Baird set a $53.00 target price on Qiagen in a research report on Friday, February 6th. Finally, JPMorgan Chase & Co. lifted their price target on Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $53.64.

Qiagen Stock Down 0.7%

NYSE:QGEN traded down $0.26 during mid-day trading on Monday, reaching $38.15. The stock had a trading volume of 1,473,493 shares, compared to its average volume of 2,227,996. The company has a market capitalization of $7.86 billion, a price-to-earnings ratio of 18.92, a price-to-earnings-growth ratio of 1.99 and a beta of 0.79. Qiagen has a 1-year low of $37.40 and a 1-year high of $57.81. The stock’s 50 day simple moving average is $42.91 and its two-hundred day simple moving average is $47.14. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The business had revenue of $540.42 million during the quarter, compared to the consensus estimate of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period last year, the firm earned $0.61 earnings per share. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. Equities analysts anticipate that Qiagen will post 2.5 EPS for the current year.

Hedge Funds Weigh In On Qiagen

A number of hedge funds and other institutional investors have recently bought and sold shares of QGEN. Danske Bank A S acquired a new position in Qiagen in the third quarter valued at approximately $36,000. Global Retirement Partners LLC boosted its stake in Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after acquiring an additional 851 shares during the period. Advisory Services Network LLC acquired a new position in Qiagen in the third quarter valued at approximately $64,000. Kestra Advisory Services LLC acquired a new position in Qiagen in the fourth quarter valued at approximately $70,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Qiagen in the fourth quarter valued at approximately $73,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.